As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors - Neurocrine Biosciences ( NASDAQ:NBIX )
Wednesday, Neurocrine Biosciences, Inc. NBIX topline data for its Phase 2 clinical study of NBI-1117568 ( NBI-'568 ) in adults with schizophrenia. NBI-'568 is the first investigational, oral, muscarinic M4 selective agonist.
| Ticker |
Sentiment |
Impact |
|
ABBV
|
Neutral
|
27 %
|
|
BMY
|
Neutral
|
27 %
|
|
NBIX
|
Neutral
|
40 %
|
